Onco-Innovations Unveils PNKP Inhibitors to Enhance Cancer Treatment Efficacy

Onco-Innovations Limited, a Canadian firm focused on cancer research and treatment, specializing in oncology, has shared details about its licensed technology involving a novel class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (Technology), which has shown, in research, the capacity to improve the effectiveness of cancer-killing agents called topoisomerase I poisons in specific cancer therapies.

This innovative technology has the potential to improve patient outcomes for certain cancers by increasing the sensitivity of cancer cells to topoisomerase I poisons. With further research and development, it could make chemotherapy more effective while simultaneously inhibiting cancer cells from repairing their DNA. This advancement has the capacity to emerge as a significant and valuable aspect of the growing worldwide cancer treatment market.

“Our technology aims to address a critical challenge, which is to overcome drug resistance in cancer treatment and stop cancer cells from being able to repair themselves. With the goal of enhancing the sensitivity of cancer cells to existing therapies, we believe we can continue moving towards improving patient outcomes. That is what drives us in our journey to transform cancer care as we position Onco-Innovations as a key player in a rapidly growing multi-billion-dollar market,” said Thomas O’Shaughnessy, CEO of Onco-Innovations.